PLSE Company Profile and Key Details

Short-term trend indicators are bearishly aligned (SMA20 -3.03%, SMA50 16.32%, SMA200 19.6%). The stock’s 14-day RSI is 50.26 (neutral), while the ATR of 1.74 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -26.65% below its high and over 53.58% above its low. Average 10-day trading volume of 380.34 thousand shares is slightly above the 3-month average of 311.82 thousand, indicating heightened recent market interest.

Pulse Biosciences, Inc. has 67.28 million shares outstanding. The public float is 17.44 million shares, elevated short interest at 15.82% of float. This equals 2.45 million shares. The short ratio is 15.22 days. Institutional investors hold 34.65% of the float. Insiders own 73.93%. DUGGAN ROBERT W holds 48.21 million shares, UECKER DARRIN has 122.87 thousand shares and Zanganeh Maky has 86.67 thousand shares. Over the past six months, insider transactions show net selling. They sold 125.00 thousand shares across 7 transactions.

Pulse Biosciences, Inc. generated EPS of -$1.08 over the past year. Five-year average earnings growth is 12.82%. Wall Street analysts project EPS growth of -1.54% annually over the next five years. Analyst sentiment is bullish. Analyst rating data shows there are 1 Strong Buy ratings, 0 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $22.00 to $22.00. The high target offers 15.3% upside. The low target suggests 15.3% downside. The mean target is $22.00. This offers 15.3% upside. Pulse Biosciences, Inc. earnings surprise history is frequent misses against expectations. The quarter that ended May 04, 2026, missed forecasts by -15.62%. The prior quarter beat by -1.89%. Over the last six quarters, Apple has recorded several small beats. These include -33.33% in October 30, 2024.

Pulse Biosciences, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $1.08. This means the shares are trading above this model’s fair value.

The stock is currently mid-range between its 52-week high and low $12.56 and $26.30. With a market capitalization of about $1.30 billion, Pulse Biosciences, Inc. is classified as a small-cap and shows higher-than-market volatility (beta ~1.63). Key stats such as the average daily volume over the past year has been around 299.37 thousand shares, trading with heavier-than-usual volume. Headquartered in Miami, CA, Pulse Biosciences, Inc. operates in the Healthcare sector and the Medical - Instruments & Supplies industry. Led by CEO Paul Arthur LaViolette, the company employs approximately 75 people and listed since May 18, 2016. Pulse Biosciences, Inc. operates as a novel bioelectric medicine company.

Pulse Biosciences, Inc. trades at a P/E ratio of -17.59, slightly below the S&P 500 average, with a price-to-sales ratio of 1757.29 and a price-to-book ratio of 19.78 reflecting a rich premium to book value. The P/FCF stands at -24.24, also below market averages. Compared to sector medians, Pulse Biosciences, Inc. P/S is trading rich, and the P/B is far higher than peers, underscoring the brand and earnings power premium investors assign to the stock.

Pulse Biosciences, Inc. (NASDAQ:PLSE) shares are flat 0.73% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Pulse Biosciences, Inc. trading at a premium to the broader market with a P/E of -17.59. Analyst sentiment is bullish, with the majority of ratings in Outperform territory and a mean price target of $25.57, suggesting 34.01% upside. Our AI forecast model points to short-term weakness (-0.84% over two weeks), a medium-term rise (40.83% over three months), and a longer-term gain (29.25% over one year), with expected trading ranges indicating moderate volatility.

Our AI price prediction model suggests that Pulse Biosciences, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -0.84%, with price expected at $18.92 by May 25, 2026, within a range of $16.86 to $20.95 3-Month Outlook: Projected rise of 40.83%, reaching $26.87 by August 07, 2026, with a range of $26.29 to $27.57. 1-Year Outlook: Projected gain of 29.25%, with price at $24.66 by May 11, 2027, within a range of $23.39 to $25.85.